OKYO Pharma (NASDAQ:OKYO) Research Coverage Started at B. Riley

B. Riley assumed coverage on shares of OKYO Pharma (NASDAQ:OKYO) in a report issued on Monday, Marketbeat.com reports. The brokerage issued a buy rating and a $5.00 target price on the stock.

OKYO has been the subject of several other research reports. Zacks Research upgraded shares of OKYO Pharma to a “hold” rating in a research report on Tuesday, September 16th. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of OKYO Pharma in a report on Tuesday, September 23rd. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of OKYO Pharma in a research report on Wednesday, October 8th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, OKYO Pharma currently has an average rating of “Hold” and a consensus price target of $6.00.

OKYO Pharma Price Performance

OKYO opened at $2.02 on Monday. The stock’s fifty day moving average is $2.22 and its 200-day moving average is $2.36. OKYO Pharma has a one year low of $0.90 and a one year high of $3.35.

Institutional Trading of OKYO Pharma

A hedge fund recently bought a new stake in OKYO Pharma stock. Citadel Advisors LLC purchased a new position in shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 15,355 shares of the company’s stock, valued at approximately $31,000. Institutional investors own 2.97% of the company’s stock.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.